NEWS & EVENTS
BIORCHESTRA Pens a Pact Worth up to $861M for Central Nervous System(CNS)-Targeted Polymeric Nanoparticle for Intravenous Delivery of Nucleic Acid Therapies
Exclusive Research and Option Agreement With Global Biopharmaceutical Company to Leverage BIORCHESTRA Targeting Technology Platform – BDDSTM – to Develop Nucleic Acid Therapies for Treatment of Neurological Disorders in Multiple Targets
CAMBRIDGE, Mass. and DAEJEON, South Korea | March 27, 2023 – BIORCHESTRA, a biotherapeutics company focused on the treatment of rare and degenerative diseases within the Central Nervous System (CNS) by leveraging the Biorchestra Drug Delivery System (BDDSTM), which combines targeted cell delivery capabilities and proprietary RNA chemistries to develop first-in-class therapeutics, today announced an exclusive research, option, and licensing agreement with a global biopharmaceutical company focused on developing transformative medicines. The companies will collaborate on an initial target with the option to expand the collaboration to include several additional targets.
[Read more…] about BIORCHESTRA Pens a Pact Worth up to $861M for Central Nervous System(CNS)-Targeted Polymeric Nanoparticle for Intravenous Delivery of Nucleic Acid TherapiesHovione & JIXING Announce an Exclusive Global License Agreement for Ophthalmology Program
Lisbon, Portugal and Shanghai, China – Hovione, the leader in spray drying and particle engineering, announced today an exclusive license agreement for a preclinical ophthalmology program, JX08, with Ji Xing Pharmaceuticals Limited (JIXING).
JIXING is a biotechnology company headquartered in Shanghai and backed by RTW Investments, LP (RTW), a leading life sciences investment firm, that is focused on advancing innovative medicines for patients with ophthalmic and cardiovascular diseases. Under the license agreement, JIXING will receive global rights to JX08 and lead the full life cycle of development from preclinical through commercialization. [Read more…] about Hovione & JIXING Announce an Exclusive Global License Agreement for Ophthalmology Program
BIORCHESTRA, SK Biopharmaceuticals collaborate to develop miRNA-targeted therapeutics
SEOUL, South Korea, Jan. 4, 2022 / PRNewswire – BIORCHESTRA and SK Biopharmaceuticals announced today that they have forged a partnership to research and develop new therapeutic compounds targeting microRNAs [1] (miRNA) for a potential treatment of epilepsy.
Under the collaboration agreement, BIORCHESTRA, a South Korea-based privately-held biotech company that develops RNA therapeutics for neurodegenerative diseases, will be responsible for target discovery, selection, and synthesis via its in-house technology.
BIORCHESTRA has a platform using antisense oligonucleotides[2] (ASO) to inhibit and regulate miRNA function, and a proprietary drug delivery system (BDDSTM) that penetrates the blood-brain barrier (BBB) and delivers RNA drugs to the brain.
SK Biopharmaceuticals, a global innovative pharmaceutical company, will validate disease-modifying targets, as well as carry out preclinical studies. [Read more…] about BIORCHESTRA, SK Biopharmaceuticals collaborate to develop miRNA-targeted therapeutics